Medicare Enrolled

Dr. Cheryl Effron, M.D.

Optician · Anaheim, CA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Low-engagement
500 S ANAHEIM HILLS RD STE 210, Anaheim, CA 92807
7149743272
In practice since 2006 (19 years)
NPI: 1861425845 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Effron from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Effron? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Effron

Dr. Cheryl Effron is an optician specialist in Anaheim, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Effron performed 4,422 Medicare services across 1,933 unique beneficiaries.

Between the years covered by Open Payments, Dr. Effron received a total of $24,634 from 38 pharmaceutical and/or device companies across 474 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in optician. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Effron is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 19% volume in CA $24,634 industry payments

Medicare Practice Summary

Medicare Utilization ↗
4,422
Medicare services
Top 19% in CA for optician
1,933
Unique beneficiaries
$55
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~233 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Destruction of precancerous skin growths, 2-14
This procedure involves the removal or destruction of two to fourteen precancerous skin lesions. It is performed to eliminate abnormal skin cells that have the potential to develop into cancer.
1,866 $6 $35
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
638 $102 $191
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
603 $69 $129
Destruction of precancerous skin growth, 1
Removal of a single precancerous skin growth. This procedure destroys abnormal skin cells to prevent them from developing into cancer.
405 $45 $149
Destruction of 15 or more precancerous skin growths
This procedure involves the removal or destruction of fifteen or more precancerous skin lesions. It is performed to treat abnormal skin cells that have the potential to develop into cancer.
358 $146 $459
Destruction of skin growths (warts/lesions), 1-14
This procedure involves the removal or destruction of one to fourteen skin growths. It is a minor surgical intervention performed on the skin surface.
335 $99 $187
Skin biopsy, tangential
A procedure to remove a sample of the first identified skin growth for laboratory examination.
55 $80 $177
Shaving of skin growth, 1.1-2.0 cm
This procedure involves shaving off a skin growth measuring between 1.1 and 2.0 centimeters from the body, arms, or legs.
32 $101 $204
Additional skin growth biopsy
Removal of a sample of an additional skin growth for laboratory examination. This code is used for each extra lesion biopsied during the same session.
25 $46 $95
Destruction of skin growth, 15 or more growths 23 $112 $241
New patient office visit (30-44 min)
An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range.
23 $84 $193
Office visit, established patient (10-19 min)
An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition.
17 $50 $78
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
16 $130 $296
Destruction of cancerous skin growth on face, 1.1-2.0 cm
This procedure involves the removal or destruction of a cancerous skin lesion located on the face, ears, eyelids, nose, lips, or mouth. The lesion treated measures between 1.1 and 2.0 centimeters in diameter.
15 $159 $377
Destruction of cancerous skin growth, 2.1-3.0 cm
This procedure involves the removal or destruction of a cancerous skin lesion measuring between 2.1 and 3.0 centimeters located on the trunk, arms, or legs.
11 $159 $352
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$24,634
Total received (2018-2024)
Avg $3,519/year across 7 years
Top 8% in CA for optician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
38
Companies
474
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,433 (62.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$5,921 (24.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$3,280 (13.3%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,394
2023
$3,164
2022
$3,723
2021
$1,692
2020
$1,184
2019
$8,426
2018
$4,051

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Dermavant Sciences, Inc.
$643
PFIZER INC.
$366
Novartis Pharmaceuticals Corporation
$254
E.R. Squibb & Sons, L.L.C.
$194
Journey Medical Corporation
$182
ABBVIE INC.
$175
Galderma Laboratories, L.P.
$146
Incyte Corporation
$139
Ortho Dermatologics, a division of Bausch Health US, LLC
$104
SUN PHARMACEUTICAL INDUSTRIES INC.
$64
Amgen Inc.
$63
UCB, Inc.
$36
Almirall LLC
$28
Top 3 companies account for 52.8% of 2024 payments
All-time payments by company (2018-2024) ›
Galderma Laboratories, L.P.
$4,319
Incyte Corporation
$2,898
Ortho Dermatologics, a division of Bausch Health US, LLC
$1,789
EPI Health, LLC
$1,720
Celgene Corporation
$1,581
Novartis Pharmaceuticals Corporation
$1,577
DERMIRA, INC.
$1,500
PFIZER INC.
$1,429
Dermavant Sciences, Inc.
$1,285
Journey Medical Corporation
$836
Almirall LLC
$770
Sun Pharmaceutical Industries Inc.
$694
Mayne Pharma Inc.
$513
Amgen Inc.
$450
E.R. Squibb & Sons, L.L.C.
$399
Arcutis Biotherapeutics, Inc.
$330
GENZYME CORPORATION
$292
AbbVie Inc.
$248
ABBVIE INC.
$218
AbbVie, Inc.
$207
UCB, Inc.
$182
Regeneron Healthcare Solutions, Inc.
$171
NOVARTIS PHARMACEUTICALS CORPORATION
$160
Janssen Biotech, Inc.
$154
LEO Pharma Inc.
$150
Aclaris Therapeutics, Inc.
$132
VYNE Pharmaceuticals Inc.
$130
SUN PHARMACEUTICAL INDUSTRIES INC.
$111
Mylan Pharmaceuticals Inc.
$94
Allergan Inc.
$60
MAYNE PHARMA INC.
$60
Lilly USA, LLC
$44
STRATA Skin Sciences, Inc.
$40
Lumenis, Inc
$25
Sandoz Inc.
$20
DUSA Pharmaceuticals, Inc.
$19
PruGen, Inc. Pharmaceuticals
$16
Merck Sharp & Dohme Corporation
$13
Top 3 companies account for 36.6% of all-time payments
Associated products mentioned in payments ›
ABSORICA (isotretinoin) · ABSORICA LD · AKLIEF · ALTRENO · AMJEVITA · ARAZLO · Absorica LD · BLU-U · BOTOX COSMETIC · BRYHALI · Bimzelx · CIBINQO · CLODERM · COSENTYX · Ceracade · Cimzia · Clindamycin Phosphate and Benzoyl Peroxide · DORYX · DUOBRII · DUPIXENT · Dermatological Psoriasis and Vitiligo Treatment · ELIDEL · ENSTILAR · EPIDUO FORTE · EUCRISA · Humira · JUBLIA · KERYDIN · Klisyri · LEVULAN KERASTICK · LIBTAYO · LITFULO · Lumenis Pulse 120H · ODOMZO · ONEXTON · OPZELURA · ORACEA · Olux · Otezla · Ozanimod · QBREXZA · REMICADE · RETIN-A-MICRO · RHOFADE · SILIQ · SIVEXTRO · SKYRIZI · SOOLANTRA · Seysara · Sitavig · Sotyktu · TALTZ · TREMFYA · TargaDox · Targadox · VTAMA · Veltin · Verdeso · Winlevi · Xolegel · ZILXI
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (63%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 8% for optician in CA.

Looking for an optician specialist in Anaheim?
Compare opticians in the Anaheim area by procedure volume, costs, and industry payment transparency.
Browse opticians nearby

Geographic Context

Opticians within 10 mi
1,060
Per 100K population
33.5
County median income
$113,702
Nearest hospital
CHAPMAN GLOBAL MEDICAL CENTER
3.9 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Effron is a clinical cardiology specialist, with above-average Medicare volume (top 19% in CA), with low-engagement industry engagement in the top 8% of CA peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Effron experienced with destruction of precancerous skin growths, 2-14?
Based on Medicare claims data, Dr. Effron performed 1,866 destruction of precancerous skin growths, 2-14 services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Effron receive payments from pharmaceutical companies?
Yes. Dr. Effron received a total of $24,634 from 38 companies across 474 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Effron's costs compare to other opticians in Anaheim?
Dr. Effron's average Medicare payment per service is $55. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Effron) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →